DUBLIN, May 14, 2021 /PRNewswire/ -- New findings
from an American College of Cardiology's (ACC) survey revealed
more than half of cardiologists (57%) believe patient
preparation may lead to better quality discussions around treatment
options for heart valve disease (HVD). Results from the ACC
CardioSurve panelist survey, sponsored by Medtronic (NYSE: MDT),
and conducted by the American College of Cardiology, garnered
responses from more than 150 cardiologists around key factors
driving treatment choices for patients with symptomatic severe
aortic stenosis. The data was published in the April 2021 Cardiology Magazine and will be
presented Sunday during the virtual symposium at ACC's
70th Annual Scientific Session, A Practical Approach
to Shared Decision-Making when Treating HVD.
More than five million Americans are currently impacted by heart
valve disease, and 1.5 million have one of the most common forms,
aortic stenosis (AS). Currently, treatment options for AS include
transcatheter aortic valve replacement (TAVR), a minimally invasive
procedure, or a surgical aortic valve replacement (SAVR), also
known as open heart surgery. However, more than half of
cardiologists surveyed (53%) feel that their symptomatic severe AS
patients are not as informed as they should be about their
treatment options.
The findings indicate physicians recognize the importance of
shared decision making to achieve individualized care for heart
valve disease patients. This reinforces new ACC/AHA Heart Valve
Disease Guidelines released in December
2020, calling for shared decision-making between patients
and their heart team when it comes to intervention choices –
particularly the decision between TAVR and SAVR.
"In light of new guidelines, it is more important than ever to
understand how to actually achieve shared decision-making goals in
clinical practice," Purvi Parwani,
M.D., director of the Women's Cardiovascular Health Clinic at Loma
Linda International Heart Institute, and panelist in the ACC
virtual symposium. "This survey gives the cardiology community
clearer insights into how to enhance the conversations we are
already having and align on patient priorities – with the ultimate
goal of achieving a more timely, individualized approach to aortic
stenosis care."
The survey drew parallels to the recent Active Living
survey by patient advocacy group
Heart-Valve-Surgery.com of more than 3,400 patients and
caregivers, showing that both physicians and patients want to
improve the doctor/patient dialogue to help create more
individualized treatment plans which can lead to improved
outcomes.
In fact, nearly 75% of cardiologists surveyed who regularly
treat AS patients said they discuss treatment options with their
patients at the time of the diagnosis (CardioSurve). Similarly, the
Active Living patient survey found that doctor/patient dialogue was
the highest reported factor in determining treatment decisions.
More than 90% of respondents who identified as a heart valve
patient said that they are influenced by conversations with their
doctors (Active Living). Yet, more than one-third of patients
(37.4%) wished they asked more questions at their doctor's
appointment during their heart valve disease treatment journey
(Active Living).
"We know patients with AS count on discussions with their
cardiologists, making it even more important to fine-tune how they
prepare for these critical decisions," said Adam Pick, patient
advocate and founder of Heart-Valve-Surgery.com. "As an advocate
for heart valve disease education, I hope these insights empower
patients to find their voice and know that their physicians value
the dialogue around their treatment goals and preferences."
The CardioSurve results also suggests key factors driving
treatment choices and the preparation for conversations can vary
between physicians and patients:
- The top three items that cardiologists believe would better
prepare their patients prior to their discussion include:
-
- Having a family member/friend attend the visit to take notes
and ask follow-up questions (59%)
- Use of a patient decision aid (53%)
- Come with a list of questions to ask during the appointment
(46%)
- The most important factor to physicians when determining the
best treatment option for patients is the risk of mortality (70% -
CardioSurve), while nearly half of patients (49% - Active Living)
cite a return to an active lifestyle as a key factor in their
treatment decision.
"As a global leader in heart valve innovation, Medtronic is
committed to advancing our structural heart therapies to standard
of care and expanding access to patients around the world," said
Nina Goodheart, president of the
Structural Heart & Aortic business, which is part of the
Cardiovascular Portfolio at Medtronic. "These survey results
demonstrate the strong collaboration by industry, medical societies
and patient advocates to improve outcomes."
ABOUT THE SURVEYS
ACC
CardioSurve
This research was designed to develop a
general understanding from U.S. cardiologists of their perceptions
regarding the discussion between cardiologists and patients about
the diagnosis and treatment of patients with Aortic Stenosis (AS).
Email invites were sent to all 437 CardioSurve panelists – current,
active US Fellows of the ACC from January
8 – February 4, 2021. A total
of 157 panelists completed the survey.
Active Living Survey
These results are based on an
online survey issued to the Heart-Valve-Surgery.com community
in April 2020, the world's largest
educational resource and community of heart valve patients. More
than 3,400 responses were received from heart valve patients and
caregivers. The respondents were a 50/50 male female split with 72%
over the age of 60 and 91% over the age of 50. Of the respondents,
94% identified as heart valve patients, 53% identified as aortic
stenosis patients.
Contacts:
|
|
|
|
Joey
Lomicky
|
Amy
Burdick
|
Medtronic
plc
|
BRG
Communications
|
+1-612-239-1823
|
+1-703-739-8343
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-survey-identifies-opportunity-to-improve-shared-decision-making-between-cardiologists-and-heart-valve-disease-patients-301291465.html
SOURCE Medtronic plc